Industry News

Premier, Inc., a leading healthcare improvement company, and the University of Texas System, one of the largest public university systems in the United States with 14 institutions and more than 221,000 students, have expanded their partnership. The UT System signed a new agreement with Premier in April 2016 to strategically integrate purchasing practices across its eight..."/>
The University of Texas System Expands Partnership with Premier Inc.
WellCare Health Plans, Inc., announced today it named Dr. Keith Wilson, M.D., medical director, effective July 5, 2016. Wilson's primary focus will be to collaborate with physicians to ensure WellCare of Florida members are receiving quality care and obtaining needed services and preventive screenings."/>
WellCare of Florida Names Dr. Keith Wilson Medical Director
Catasys, Inc., a provider of proprietary data, predictive analytics, and modeling based behavioral health management services for health plans, announced today that it has launched its On Trak™- H solution in Georgia with one of the nation's leading health plans. The plan's eligible commercial and Medicare Advantage members will be covered under On Trak- H, a 52- week, multi-phase program in which enrolled members receive medical and..."/>
Catasys Expands Rollout of OnTrak-H Solution in Georgia with Leading National Health Insurance Provider
Cynosure, Inc. today announced that it has received a medical device license issued by Health Canada to market SculpSure ® for non-invasive lipolysis of the abdomen and flanks. That's great news for Canadians, who– for the first time– will for be able to eliminate areas of unwanted fat with a non-invasive, 25- minute laser treatment that requires no surgery, no anesthesia and no downtime. "SculpSure is setting the new standard in nonsurgical..."/>
Cynosure Receives Health Canada Authorization to Market SculpSure®
Regeneron Pharmaceuticals, Inc. today announced the winners of the fourth annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and foster talented early-career biomedical scientists. This year, Regeneron awarded $155,000 in prize money to 10 awardees and two institutions. "These talented postdoctoral and graduate student winners have shown significant dedication and promise early in their..."/>
Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation
SCYNEXIS, Inc. today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases, for the sale of its cyclophilin inhibitor assets. Cypralis will also acquire all patents, patent applications and know-how related to the acquired portfolio."/>
SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
Enzymotec Ltd., today announced that it will hold its 2016 Annual General Meeting of Shareholders on Thursday, August 25, 2016. The record date for shareholders entitled to vote at the Meeting is Monday, July 18, 2016.. The Meeting is being called for the following purposes:."/>
Enzymotec Ltd. Calls for its 2016 Annual General Meeting of Shareholders
DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company will ring the Nasdaq Opening Bell on Thursday, July 14 in honor of its recent listing on Nasdaq. Members of the DelMar Pharmaceuticals corporate team including Jeffrey Bacha, Chairman and CEO, will ring the opening bell in celebration of..."/>
DelMar Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell on July 14
IntelGenx to Initiate Phase 1 Trial of Montelukast
Viveve Medical, Inc., a medical technology company focused on women's health, today announced that company representatives have been invited to ring the Nasdaq Stock Market Opening Bell on Monday, July 18, 2016, at the Nasdaq MarketSite in New York City. Patricia Scheller, chief executive officer of Viveve, and Scott Durbin, Viveve's chief financial officer, will ring the opening bell in celebration of the listing of Viveve's common stock on Nasdaq."/>
Viveve(R) to Ring the Nasdaq Stock Market Opening Bell to Celebrate Its Listing
Pfizer reported on Tuesday that it has received US Food and Drug Administration approval for an expanded age indication of Prevnar 13 to include adults aged 18-49.. The company said the expanded age indication is in addition to the already approved indication for adults 50 years and older for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae serotypes. Following the FDA's decision,..."/>
Pfizer receives FDA approval for Prevnar 13 expanded age indication against S. pneumoniae
Aytu BioScience, Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the addition of John Donofrio, Jr., a 24- year pharmaceutical veteran and U.S. CFO of a global specialty pharmaceutical company, and Gary Cantrell, a seasoned pharmaceutical executive with 30 years in the life sciences industry at global pharmaceutical companies and specialty life..."/>
Aytu BioScience Strengthens Board with the Appointment of Two Pharmaceutical Industry Veterans as Independent Directors
Pfizer Inc. announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% in the online issue of the Journal of the American Academy of Dermatology.. “Atopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults."/>
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
Event Cardio Group, Inc. closed its acquisition of National Cardiac Monitoring Center in Glenelg, Maryland in a Stock Purchase Agreement worth approximately $5 million in a combination of cash and ECGI common stock. NCMC has been providing cardiac diagnostic services since 1986. It provides a range of cardiac monitoring modalities including Mobile Cardiac Telemetry, wireless and trans-telephonic cardiac event monitoring, 24/ 48- hour digital Holter..."/>
Event Cardio Group Acquires National Cardiac Monitoring Center
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 28, 2016 to discuss the 2nd quarter 2016 results. The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260. Canadian participants should call 1-855-669-9657. Participants should ask to be joined into the..."/>
Teligent, Inc. To Hold Conference Call For 2nd Quarter 2016 Results
InVivo Therapeutics Holdings Corp. today announced that Health Canada has approved the company’ s Investigational Testing Authorization application to commence clinical studies in Canada. The authorization will allow the company to enroll Canadian patients into the ongoing INSPIRE study once a Canadian site is open for enrollment. InVivo currently is in late stage conversation with various Canadian Research Ethics Boards and expects to announce..."/>
InVivo Therapeutics Receives Investigational Testing Authorization from Health Canada
CytoSorbents Corporation, a critical care immunotherapy leader commercializing its flagship CytoSorb ® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed a formal exclusive distribution agreement with Medial, Ltd., to distribute CytoSorb ® in Hungary. In a separate agreement, Meditrade Ltd. will distribute CytoSorb ® for all..."/>
CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb® to Hungary, Czech Republic, Slovakia, and Poland
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted.. Announced that the FDA granted the Company a waiver of the..."/>
Intellipharmaceutics Announces Second Quarter 2016 Results
Abaxis, Inc., a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the first quarter fiscal year 2017, ended June 30, 2016. The call will be at 4:15 p.m. ET on Thursday, July 21, 2016. The Company will report financial results for the first quarter fiscal year 2017 after..."/>
Abaxis To Report First Quarter Fiscal Year 2017 Financial Results On Thursday, July 21, 2016
Seattle Genetics, Inc. announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:."/>
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2016 Financial Results on July 26, 2016
Imprivata’ s stock price. Transaction valued at approximately $544 million. SAN FRANCISCO& LEXINGTON, Mass.---- Imprivata ®, the healthcare IT security company, announced that it has entered into a definitive agreement to be acquired by an affiliate of Thoma Bravo, LLC, a leading private equity investment firm."/>
Imprivata Agrees to Be Acquired by Thoma Bravo
Nuvo Pharmaceuticals Inc. today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial in Germany to study Pennsaid 2% for the treatment of acute ankle sprains. Topline results of the Trial are expected to be available in late Q2 or early Q3 2017. The Trial is subject to approval by German regulatory authorities and the ethical review committee. Pennsaid 2% is currently approved by the U.S."/>
Nuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials961 Articles
Information Technology902 Articles
Consumer Discretionary762 Articles
Industrials600 Articles
Health Care596 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at